¿Cómo se compara el ratio PS de DOA con empresas similares?

DOA es un buen valor basado en su ratio Price-To-Sales (9.1x) comparado con la media de empresas similares (16.1x).

¿Cómo se compara el ratio PS de DOA con el de otras empresas de la industria DE Biotechs ?

DOA es cara en función de su ratio Price-To-Sales (9.1x) en comparación con la media de la industria German Biotechs (12.6x).

¿Cuál es el ratio PS de DOA comparado con su ratio PS justo? Este es el ratio PS esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

DOA es un buen valor basado en su ratio Price-To-Sales (9.1x) comparado con el ratio justo estimado Price-To-Sales (12.9x).

¿Cuál es el precio justo de DOA si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

Datos insuficientes para calcular el valor justo de DOA para el análisis de valoración.

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Soligenix (DB:DOA) - Cotización, noticias y análisis

Resumen de acción DOA

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Saber más

Análisis fundamental de DOA
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	2/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 75.85%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 1.5% al año durante los próximos 3 años

No tiene una capitalización de mercado significativa (€9M)

Tiene unos ingresos inferiores a 1 millón de dólares ($949K)

Patrimonio neto negativo

+ 3 riesgos adicionales

Competidores de Soligenix, Inc.

Medigene

XTRA:MDG1

€20.6m

co.don

XTRA:CNW

€6.5m

Epigenomics

DB:ECX

€1.6m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Soligenix
Precios históricos de las acciones
Precio actual de la acción	US$5.85
Máximo en las últimas 52 semanas	US$14.11
Mínimo de 52 semanas	US$5.58
Beta	1.74
1Cambio en 1 mes	0%
Variación en 3 meses	-5.11%
Cambio de 1 año	-10.53%
3Variación en 3 años	-73.29%
Variación en 5 años	-71.94%
Variación desde la OPV	-77.87%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	DOA	DE Biotechs	Mercado DE
7D	0%	0.8%	0.8%
1Y	-10.5%	-18.3%	8.6%

Rentabilidad vs. Industria: DOA superó a la industria German Biotechs, que obtuvo un rendimiento del -18.3% el año pasado.

Rentabilidad vs. Mercado: DOA obtuvo unos resultados inferiores a los del mercado German, que fueron del 8.6% el año pasado.

Volatilidad de los precios

Is DOA's price volatile compared to industry and market?
DOA volatility
DOA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: DOA no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de DOA en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1987	14	Christopher Schaber	www.soligenix.com

Resumen de fundamentos de Soligenix, Inc.

¿Cómo se comparan los beneficios e ingresos de Soligenix con su capitalización de mercado?
Estadísticas fundamentales de DOA
Capitalización bursátil	€7.89m
Beneficios(TTM)	-€12.59m
Ingresos (TTM)	€865.50k

9.1x

Ratio precio-ventas (PS)

-0.6x

Ratio precio-beneficio (PE)

¿Está DOA sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de DOA
Ingresos	US$948.91k
Coste de los ingresos	US$550.82k
Beneficio bruto	US$398.09k
Otros gastos	US$14.20m
Beneficios	-US$13.80m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.45
Margen bruto	41.95%
Margen de beneficio neto	-1,454.12%
Ratio deuda/patrimonio	-400.6%

¿Cómo se ha desempeñado DOA a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción DOA

Recompensas

Análisis de riesgos

Competidores de Soligenix, Inc.

XTRA:MDG1

€20.6m

XTRA:CNW

€6.5m

DB:ECX

€1.6m

BST:BPXA

€772.4k

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Soligenix, Inc.

9.1x

-0.6x

Beneficios e Ingresos